8.1 Cellular, Acellular & Matrix-Like Advanced Biologics (CTPs)

8.1 Cellular, Acellular & Matrix-Like Advanced Biologics (CTPs)

Core Clinical Principle: Cellular and Tissue-Based Products (CTPs)—historically designated as "skin substitutes"—are advanced biological therapeutics engineered to re-establish physiological cell-signaling networks in recalcitrant chronic wounds. Rather than serving as permanent anatomical transplants, allogeneic and xenogeneic CTPs act as bioinductive and biomimetic templates. They deliver physiological scaffolding, downregulate excessive matrix metalloproteinases (MMPs), and stimulate endogenous host cellular migration, granulation, and re-epithelialization.

In chronic, non-healing wounds such as diabetic neuropathic foot ulcers (DFUs) and venous leg ulcers (VLUs), the microenvironment is locked in a self-perpetuating, hyper-inflammatory state. Native dermal fibroblasts become phenotypically senescent, extracellular matrix (ECM) proteins undergo rapid degradation by unrestrained neutral proteases, and essential endogenous growth factors are enzymatically destroyed. When rigorous, evidence-based standard of care fails to kickstart the healing trajectory, advanced biological therapies become clinically indispensable.

---

Classification of Cellular & Tissue-Based Products (CTPs)

The American Society for Testing and Materials (ASTM F3163) and contemporary wound care consensus frameworks categorize CTPs into three major biological classes based on their cellular viability, source donor tissue, and structural composition:

+-------------------------------------------------------------------------------------------------+
|                        CTP / SKIN SUBSTITUTE CLASSIFICATION MATRIX                              |
+-------------------------------------------------------------------------------------------------+
| 1. LIVING CELLULAR CONSTRUCTS                                                                   |
|    • Contain metabolically active allogeneic human cells (fibroblasts, keratinocytes)           |
|    • Actively synthesize and secrete physiological cocktails of cytokines and growth factors    |
|    • Examples: Apligraf (bilayered living cellular), Dermagraft (dermal fibroblast construct)   |
+-------------------------------------------------------------------------------------------------+
| 2. ACELLULAR DERMAL & EXTRACELLULAR MATRICES (ACMs / ECMs)                                      |
|    • Decellularized human allografts, animal xenografts, or placental membrane tissues          |
|    • Structural collagenous scaffolding preserved; intact native GAGs and bound growth factors  |
|    • Non-immunogenic, cell-free templates that direct host cellular ingrowth and remodeling     |
|    • Examples: OASIS SIS (porcine intestine), EpiFix (dHACM), MatriStem (porcine UBM)           |
+-------------------------------------------------------------------------------------------------+
| 3. SYNTHETIC & COMPOSITE SCAFFOLDS                                                              |
|    • Bioabsorbable synthetic polymers or composite bio-matrices with temporary synthetic layers |
|    • Provide controlled porosity, structural stability, and vapor barrier protection            |
|    • Example: Integra Bilayer Wound Matrix (bovine collagen-GAG + silicone epidermal shield)    |
+-------------------------------------------------------------------------------------------------+

---

Living Cellular Constructs

Living cellular constructs contain viable, allogeneic human cells derived from screened neonatal foreskins. Neonatal cells possess superior proliferative capacity, increased telomerase activity, lower immunogenicity, and higher paracrine growth factor output compared to adult somatic cells.

1. Apligraf (Graftskin)

Apligraf is an FDA-approved, living, bilayered cellular construct designed to replicate the anatomical and functional architecture of human skin:

• Dermal Layer: Composed of a porous, acid-extracted bovine Type I collagen sponge populated with living human neonatal foreskin dermal fibroblasts. The fibroblasts remodel the collagen matrix and produce human extracellular matrix proteins.
• Epidermal Layer: Formed by an overlying, stratified, differentiated layer of living human neonatal foreskin keratinocytes, complete with an organized stratum basale, stratum spinosum, stratum granulosum, and a non-living stratum corneum.
• Biosynthetic Mechanism of Action: Apligraf does not permanently engraft; DNA testing reveals that donor cells typically disappear from the wound bed within 4 to 8 weeks. Its primary therapeutic efficacy stems from dynamic, sustained paracrine signaling. The living keratinocytes and fibroblasts establish an active biological dialogue with host tissue, continuously secreting physiological concentrations of:
  • Platelet-Derived Growth Factor (PDGF-AA, PDGF-BB): Potent chemoattractant for host fibroblasts and macrophages.
  • Vascular Endothelial Growth Factor (VEGF-A): Stimulates capillary endothelial sprouting (angiogenesis).
  • Transforming Growth Factor-Beta (TGF-β1, TGF-β3): Regulates matrix synthesis and promotes organized dermal remodeling.
  • Basic Fibroblast Growth Factor (bFGF / FGF-2) and Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF): Drive fibroplasia and epithelial edge activation.
  • Interleukins (IL-6, IL-8): Modulate localized inflammatory resolution.
• FDA-Approved Indications:
  1. Venous Leg Ulcers (VLUs): Indicated for full-thickness VLUs of greater than 1 month duration that have failed to respond to conventional compression therapy.
  2. Diabetic Foot Ulcers (DFUs): Indicated for full-thickness neuropathic DFUs of greater than 3 weeks duration extending through the dermis without tendon, muscle, capsule, or bone involvement, that have failed standard diabetic ulcer therapy.
• Clinical Handling & Storage: Apligraf is shipped living in a nutrient agarose medium sealed in a plastic pouch at room temperature (20°C to 23°C / 68°F to 73°F). It must never be frozen or refrigerated. Prior to fenestration and application, it is removed using sterile blunt plastic forceps, thoroughly rinsed with sterile saline, and placed with the epidermal (matte/dull) side facing upward and the dermal (glossy) collagen side facing down against the prepared wound bed.

2. Dermagraft

Dermagraft is an FDA-approved, cryopreserved, living human dermal substitute consisting of allogeneic human neonatal dermal fibroblasts seeded onto a bioabsorbable polyglactin-910 (Vicryl) knitted mesh scaffold:

• Tissue Engineering Process: Neonatal fibroblasts are seeded onto the Vicryl mesh within an automated closed bioreactor system. As the fibroblasts proliferate, they fill the 3D scaffold interstices and secrete human structural proteins (collagen types I and III, fibronectin, tenascin) and glycosaminoglycans, creating a metabolically active neodermis. The polyglactin-910 mesh hydrolyzes spontaneously over 3 to 4 weeks into lactic and glycolic acid.
• Biosynthetic Function: Dermagraft delivers a living dermal matrix that secretes human matrix proteins, cytokines, and angiogenic factors (VEGF, bFGF, PDGF-AA, TGF-β1, keratinocyte growth factor [KGF/FGF-7]). These signals promote host microvascular neovascularization and stimulate host keratinocyte migration across the viable bed.
• FDA-Approved Indication: Indicated for the treatment of full-thickness neuropathic diabetic foot ulcers of greater than 6 weeks duration that extend through the dermis but without muscle, tendon, joint capsule, or bone involvement, in patients with adequate arterial blood supply.
• Thawing & Preparation Protocol: Dermagraft is stored cryopreserved at -75°C to -85°C. It requires a standardized, timed thawing protocol utilizing a 37°C sterile water bath for 1.5 to 2 minutes, followed by a sequence of three serial rinses in sterile 0.9% saline. Because cell viability drops sharply after thaw, Dermagraft must be implanted within 30 minutes of thawing. It is completely non-immunogenic because fibroblasts express negligible levels of HLA-DR.

---

Acellular Dermal & Extracellular Matrices

Acellular matrices are non-living, cell-free biomaterials derived from human cadaveric skin (allografts), mammalian tissues (xenografts), or placental membranes. Through proprietary decellularization processes involving mechanical agitation, enzymatic lysis, and detergent extraction, all cellular antigens, nucleic acids, and membrane lipids are eradicated, eliminating the risk of immunological rejection while preserving the native 3D ultrastructure and biological signaling cues.

1. Porcine Small Intestinal Submucosa (OASIS SIS Wound Matrix)

Derived from the submucosal layer of porcine small intestine, OASIS SIS is an acellular extracellular matrix scaffold:

• Molecular Composition: Composed predominantly of Type I collagen (approximately 90%), with lesser amounts of Type III, IV, and VI collagen. It retains an intact native glycosaminoglycan (GAG) architecture, including hyaluronic acid, heparin, chondroitin sulfate A, and dermatan sulfate, as well as glycoproteins such as fibronectin and laminin.
• Endogenous Growth Factors: The gentle decellularization process preserves native signaling molecules embedded within the matrix, notably basic fibroblast growth factor (FGF-2 / bFGF), transforming growth factor-beta (TGF-β), and connective tissue growth factor (CTGF).
• Mechanism: When hydrated and secured into a clean wound bed, host inflammatory cells and capillary endothelial cells rapidly infiltrate the porous collagenous channels. Host collagenases gradually remodel the xenogeneic scaffold, replacing it with organized autologous tissue while releasing embedded matrikines that stimulate local healing.

2. Dehydrated Human Amnion/Chorion Membrane (dHACM, EpiFix)

Placental tissues possess unique biological and immunomodulatory properties evolved to protect and nourish the developing fetus:

• Anatomical Layers: Comprises an epithelial monolayer, a robust basement membrane (rich in Type IV collagen, laminin, and nidogen), and a fibrous stromal/chorionic layer. Processing cleans, dehydrates, and sterilizes the tissue (e.g., the PURION process) while preserving native cytokine architecture.
• Cytokine Reservoir: Bioassays identify over 40 regulatory cytokines and growth factors stored within dHACM, including epidermal growth factor (EGF), bFGF, PDGF-AA, PDGF-BB, TGF-α, TGF-β1, VEGF, and tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2). The TIMP content actively neutralizes excess host MMPs in the chronic wound fluid.
• Immunological Privilege & Anti-Inflammatory Effects: Placental membranes express Human Leukocyte Antigen G (HLA-G), a non-classical MHC Class I molecule that directly binds inhibitory receptors on maternal natural killer (NK) cells and cytotoxic T-cells, inducing immune tolerance. Amniotic membranes display negligible expression of HLA-A, HLA-B, HLA-C, and zero HLA-DR, preventing immunological rejection. Furthermore, dHACM suppresses pro-inflammatory macrophage M1 polarization and drives the phenotypic switch to pro-regenerative M2 macrophages.

3. Urinary Bladder Matrix (UBM, MatriStem / ACell)

Derived from the decellularized porcine urinary bladder:

• Ultrastructure: Uniquely preserves both the intact epithelial basement membrane on one surface and the deeper lamina propria on the opposing surface. The basement membrane side is rich in Type IV and Type VII collagen, laminin, and perlecan, providing a smooth substratum for rapid epithelial cell attachment and epiboly. The lamina propria side presents an open, porous collagenous network that facilitates capillary angiogenesis and fibroblast infiltration.
• Matrikine Signaling: Enzymatic degradation of UBM by host collagenases releases cryptic peptide fragments (matrikines) that possess potent chemotactic properties, recruiting endogenous circulating bone marrow-derived progenitor cells and CD34+ mesenchymal stem cells to the repair site.

4. Bilayer Wound Matrix (Integra)

Integra Bilayer Wound Matrix is a synthetic-biological composite scaffold engineered for full-thickness dermal loss (e.g., burns, trauma, post-oncologic resection, deep chronic wounds with exposed bone or tendon):

• Dermal Replacement Layer: A 2-mm thick porous, bioabsorbable scaffold synthesized from cross-linked bovine tendon Type I collagen and chondroitin-6-sulfate (a glycosaminoglycan derived from shark cartilage). The specific cross-linking density and pore size (70 to 120 μm) are engineered to match the migratory kinetics of human dermal fibroblasts and endothelial capillary sprouts.
• Epidermal Shield Layer: An outer temporary layer of semi-permeable polysiloxane (silicone) polymer (0.1 mm thick). The silicone membrane acts as a synthetic epidermis, controlling water vapor loss (transepidermal water loss [TEWL]), providing mechanical stability, and sealing the wound bed against exogenous bacterial invasion.
• Neovascularization Kinetics & The Two-Stage Surgical Protocol:
  • Stage 1 (Cellular Infiltration & Neodermis Formation): The matrix is placed over debrided, viable tissue (even over exposed periosteum or paratenon) and secured with staples or sutures. Over 14 to 21 days, host fibroblasts and capillary endothelial cells migrate into the collagen-GAG scaffold. As neovascularization progresses, the matrix undergoes a visible color transformation from a pale peach/pink hue to a characteristic light yellow-orange or gold color. The collagen scaffold gradually biodegrades while host cells deposit autologous collagen, forming a vascularized neodermis.
  • Stage 2 (Silicone Peeling & Epidermal Autografting): Once neovascularization is complete (confirmed by capillary refill beneath the silicone), the silicone membrane is carefully grasped with forceps and peeled away from the neodermis. A very thin split-thickness autograft (STSG, 0.004–0.006 inches) or epidermal autograft is applied directly onto the neodermis, achieving definitive, durable skin closure with minimal donor-site morbidity.

---

Comprehensive Comparative Matrix of Major CTPs

---

Medicare Coverage Context for CTPs (Current as of the CY2026 Fee Schedule)

Coverage and payment rules for skin substitutes changed substantially in 2025–2026, and they differ by Medicare Administrative Contractor (MAC). Physicians should check their own MAC before applying a product.

What Legacy Policies Typically Require

1. Documented standard of care first: Most policies require at least 4 weeks of documented, optimal care before a skin substitute is applied—offloading for diabetic foot ulcers; continuous compression for venous leg ulcers; debridement; infection control; moisture balance; and management of glucose, nutrition, and smoking.
2. Evidence of inadequate healing: The withdrawn LCDs used failure to achieve at least 50% area reduction after 4 weeks for diabetic foot ulcers, a threshold rooted in Sheehan et al. (2003), in which about 9% of ulcers with less than roughly half-area reduction at 4 weeks healed by 12 weeks, compared with 58% of those that reached it.
3. Adequate perfusion and a clean bed: Arterial perfusion must be assessed and adequate, and the wound must be free of necrotic tissue and active infection (including untreated osteomyelitis). Specific numeric perfusion cutoffs vary by policy.
4. Measurement at every application: Record length, width, depth, and area before each application, along with the product, size used, amount discarded, and lot number.
5. Application limits: Limits vary. For example, the legacy Novitas policy (L35041) considers more than 10 applications to a single wound within 12 weeks not reasonable and necessary.
6. Stopping rule: If the wound does not measurably improve after several applications, reassess the diagnosis and plan rather than continuing indefinitely.

Clinical Pearl: Coverage policy is not the same as clinical evidence. Randomized trials support specific products for specific indications (for example, Apligraf and Dermagraft for diabetic foot ulcers, and Apligraf for venous leg ulcers). Many other products are regulated as human tissue (361 HCT/Ps) or cleared through 510(k) without large trials.